Cargando…
A Peptide Targeted Contrast Agent Specific to Fibrin-Fibronectin Complexes for Cancer Molecular Imaging with MRI
[Image: see text] A peptide targeted contrast agent, CLT1-(Gd-DTPA), was synthesized for molecular imaging of fibronectin−fibrin complexes in tumor tissue with magnetic resonance imaging (MRI). The T(1) and T(2) relaxivities of CLT1-(Gd-DTPA) were 4.22 and 4.45 mM(−1) s(−1) at 3 T, respectively. The...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2008
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2651601/ https://www.ncbi.nlm.nih.gov/pubmed/19053180 http://dx.doi.org/10.1021/bc800211r |
_version_ | 1782165167127134208 |
---|---|
author | Ye, Furong Jeong, Eun-Kee Jia, Zhanjun Yang, Tianxin Parker, Denis Lu, Zheng-Rong |
author_facet | Ye, Furong Jeong, Eun-Kee Jia, Zhanjun Yang, Tianxin Parker, Denis Lu, Zheng-Rong |
author_sort | Ye, Furong |
collection | PubMed |
description | [Image: see text] A peptide targeted contrast agent, CLT1-(Gd-DTPA), was synthesized for molecular imaging of fibronectin−fibrin complexes in tumor tissue with magnetic resonance imaging (MRI). The T(1) and T(2) relaxivities of CLT1-(Gd-DTPA) were 4.22 and 4.45 mM(−1) s(−1) at 3 T, respectively. The targeted contrast agent specifically bound to tumor tissue and resulted in significant tumor contrast enhancement at a dose of 0.1 mmol Gd/kg for at least 60 min in mice bearing HT-29 human colon carcinoma xenografts as shown in dynamic MR images. In contrast, a control nontargeted contrast agent, Gd(DTPA-BMA), was cleared rapidly with little tumor enhancement 60 min postinjection. Tumor enhancement with CLT1-(Gd-DTPA) was significantly reduced after coinjection with a 3-fold excess of free CLT1 peptide. The preliminary study has shown that CLT1-(Gd-DTPA) can specifically bind to the fibrin−fibronectin complexes in tumor tissues, resulting in significant tumor enhancement. The targeted contrast agent has a potential for cancer molecular imaging with MRI. |
format | Text |
id | pubmed-2651601 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-26516012009-03-20 A Peptide Targeted Contrast Agent Specific to Fibrin-Fibronectin Complexes for Cancer Molecular Imaging with MRI Ye, Furong Jeong, Eun-Kee Jia, Zhanjun Yang, Tianxin Parker, Denis Lu, Zheng-Rong Bioconjug Chem [Image: see text] A peptide targeted contrast agent, CLT1-(Gd-DTPA), was synthesized for molecular imaging of fibronectin−fibrin complexes in tumor tissue with magnetic resonance imaging (MRI). The T(1) and T(2) relaxivities of CLT1-(Gd-DTPA) were 4.22 and 4.45 mM(−1) s(−1) at 3 T, respectively. The targeted contrast agent specifically bound to tumor tissue and resulted in significant tumor contrast enhancement at a dose of 0.1 mmol Gd/kg for at least 60 min in mice bearing HT-29 human colon carcinoma xenografts as shown in dynamic MR images. In contrast, a control nontargeted contrast agent, Gd(DTPA-BMA), was cleared rapidly with little tumor enhancement 60 min postinjection. Tumor enhancement with CLT1-(Gd-DTPA) was significantly reduced after coinjection with a 3-fold excess of free CLT1 peptide. The preliminary study has shown that CLT1-(Gd-DTPA) can specifically bind to the fibrin−fibronectin complexes in tumor tissues, resulting in significant tumor enhancement. The targeted contrast agent has a potential for cancer molecular imaging with MRI. American Chemical Society 2008-12-03 2008-12-17 /pmc/articles/PMC2651601/ /pubmed/19053180 http://dx.doi.org/10.1021/bc800211r Text en Copyright © 2008 American Chemical Society http://pubs.acs.org This is an open-access article distributed under the ACS AuthorChoice Terms & Conditions. Any use of this article, must conform to the terms of that license which are available at http://pubs.acs.org. 40.75 |
spellingShingle | Ye, Furong Jeong, Eun-Kee Jia, Zhanjun Yang, Tianxin Parker, Denis Lu, Zheng-Rong A Peptide Targeted Contrast Agent Specific to Fibrin-Fibronectin Complexes for Cancer Molecular Imaging with MRI |
title | A Peptide Targeted Contrast Agent Specific to Fibrin-Fibronectin Complexes for Cancer Molecular Imaging with MRI |
title_full | A Peptide Targeted Contrast Agent Specific to Fibrin-Fibronectin Complexes for Cancer Molecular Imaging with MRI |
title_fullStr | A Peptide Targeted Contrast Agent Specific to Fibrin-Fibronectin Complexes for Cancer Molecular Imaging with MRI |
title_full_unstemmed | A Peptide Targeted Contrast Agent Specific to Fibrin-Fibronectin Complexes for Cancer Molecular Imaging with MRI |
title_short | A Peptide Targeted Contrast Agent Specific to Fibrin-Fibronectin Complexes for Cancer Molecular Imaging with MRI |
title_sort | peptide targeted contrast agent specific to fibrin-fibronectin complexes for cancer molecular imaging with mri |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2651601/ https://www.ncbi.nlm.nih.gov/pubmed/19053180 http://dx.doi.org/10.1021/bc800211r |
work_keys_str_mv | AT yefurong apeptidetargetedcontrastagentspecifictofibrinfibronectincomplexesforcancermolecularimagingwithmri AT jeongeunkee apeptidetargetedcontrastagentspecifictofibrinfibronectincomplexesforcancermolecularimagingwithmri AT jiazhanjun apeptidetargetedcontrastagentspecifictofibrinfibronectincomplexesforcancermolecularimagingwithmri AT yangtianxin apeptidetargetedcontrastagentspecifictofibrinfibronectincomplexesforcancermolecularimagingwithmri AT parkerdenis apeptidetargetedcontrastagentspecifictofibrinfibronectincomplexesforcancermolecularimagingwithmri AT luzhengrong apeptidetargetedcontrastagentspecifictofibrinfibronectincomplexesforcancermolecularimagingwithmri AT yefurong peptidetargetedcontrastagentspecifictofibrinfibronectincomplexesforcancermolecularimagingwithmri AT jeongeunkee peptidetargetedcontrastagentspecifictofibrinfibronectincomplexesforcancermolecularimagingwithmri AT jiazhanjun peptidetargetedcontrastagentspecifictofibrinfibronectincomplexesforcancermolecularimagingwithmri AT yangtianxin peptidetargetedcontrastagentspecifictofibrinfibronectincomplexesforcancermolecularimagingwithmri AT parkerdenis peptidetargetedcontrastagentspecifictofibrinfibronectincomplexesforcancermolecularimagingwithmri AT luzhengrong peptidetargetedcontrastagentspecifictofibrinfibronectincomplexesforcancermolecularimagingwithmri |